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Investigating complex I deficiency in Purkinje cells and synapses in patients with
mitochondrial disease
Aims: Cerebellar ataxia is common in patients with
mitochondrial disease, and despite previous neuro-
pathological investigations demonstrating vulnerability of
theolivocerebellar pathway inpatientswithmitochondrial
disease, the exact neurodegenerative mechanisms are still
not clear. We use quantitative quadruple immunofluores-
cence to enable precise quantification of mitochondrial
respiratory chain protein expression inPurkinje cell bodies
and their synaptic terminals in the dentate nucleus.
Methods: We investigated NADH dehydrogenase
[ubiquinone] 1 alpha subcomplex subunit 13 protein
expression in 12 clinically and genetically defined patients
with mitochondrial disease and ataxia and 10 age-
matched controls. Molecular genetic analysis was per-
formed to determine heteroplasmy levels of mutated
mitochondrial DNA in Purkinje cell bodies and inhibitory
synapses.Results:Ourdata reveal that complex Ideficiency
is present in both Purkinje cell bodies and their inhibitory
synapses which surround dentate nucleus neurons.
Inhibitory synapses are fewer and enlarged in patients
which could represent a compensatory mechanism.
Mitochondrial DNA heteroplasmy demonstrated similarly
high levels of mutated mitochondrial DNA in cell bodies
and synapses. Conclusions: This is the first study to use a
validated quantitative immunofluorescence technique
to determine complex I expression in neurons and
presynaptic terminals, evaluating the distribution of res-
piratory chain deficiencies and assessing the degree of
morphological abnormalities affecting synapses. Respira-
tory chain deficiencies detected in Purkinje cell bodies and
their synapses and structural synaptic changes are likely to
contribute toalteredcerebellar circuitryandprogressionof
ataxia.
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Introduction
Mitochondrial diseases are a clinically heterogeneous
group of genetic disorders underpinned by mitochondrial
respiratory chain dysfunction. The mitochondrial respira-
tory chain is responsible for the generation of ATP via
oxidative phosphorylation (OXPHOS) and is under dual
genetic control [1]. Mitochondrial disease can be caused
by either mutations in the mitochondrial DNA (mtDNA)
(point mutations or rearrangements) or mutations in
nuclear DNA (nDNA)-encoded proteins involved in
mitochondrial homeostasis [2].
Neurons are exquisitely sensitive to fluctuations in
mitochondrial function and ATP generation. They possess
a highly specialized architecture with long processes
extending from the cell body to the distal synapses project-
ing onto other neuronal cells. Energy supply to these
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distal regions is achieved via motor protein-assisted
mitochondrial transport along the axons [3]. Sites with
increasedATPdemandhave ahigher density of mitochon-
dria [4], and synapses are among the most energetically
active parts of a neuron. In the synapse, mitochondria
regulate numerous processes including synaptic vesicle
exocytosis and recycling, and calciumbuffering [5–7]. It is,
therefore, not surprising that neurological deficits are
widespread in patients with mitochondrial disease, and
symptoms may be manifold including seizures, cognitive
decline and cerebellar ataxia [8]. Recent studies indicate
that approximately 70% of patients recruited to the UK
MRCMitochondrial Disease Patient Cohort are affected by
cerebellar ataxiawhich is debilitating and progressive.The
cerebellumisparticularlyvulnerable tomitochondrial dys-
function, and neuropathological investigation of patients
often reveals cerebellar atrophy, Purkinje cell loss and
mitochondrial respiratory chain deficiencies of complex I
in remaining cells [9–14].
Evidence of synaptic pathology has been documented
in post-mortem brain tissue from patients with mito-
chondrial disease, including decreased synaptophysin
immunoreactivity and swollen (when present) calbindin-
positive endings to the dentate nucleus neurons
[9,10]. Genetic manipulation of proteins involved in
mitochondrial fission and fusion in cultured neurons [15]
and mice [16] has revealed mitochondrial retraction
towards the cell body accompanied by striking alterations
in synaptic integrity.Observedchanges includea reduction
in dendritic spine density, decreased synaptic formation
and delayed transmitter release frequency [15,16]. Artifi-
cial inhibition of mitochondrial respiratory chain function
in vivo and in vitro revealed the importance of ATP levels in
controlling synaptic energetic state and in maintaining
synaptic integrity and functionality [17,18]. Recent work
has recognized synaptic dysfunction and degeneration in
response to mitochondrial dysfunction as an early feature
in neurodegenerative disease [19,20].
In this study, we aimed to clarify the degree of deficiency
and changes in synaptic structures in the cerebellum of
patients with adult-onset mitochondrial disease. The cer-
ebellum is a clinically relevant and well-defined structure
in which detailed neuropathological studies have been
performed previously in patients with mitochondrial
disease; however, there have been no in depth studies
investigating the presence of respiratory chain defects or
structural changes affecting the synapse. We quantified
respiratory chain deficiency in Purkinje cells and their
gamma aminobutyric acid (GABA)-ergic synapses con-
tacting neurons in the dentate nucleus, evaluating
presynaptic terminal structural characteristics.
Materials and methods
Brain tissue samples
Formalin-fixed paraffin-embedded (FFPE) and frozen cer-
ebellum tissue from 12 adult patients with clinically and
genetically defined mtDNA disease was obtained from the
Newcastle Brain Tissue Resource (NBTR), while cerebel-
lum tissue from 10 aged-matched controls was obtained
from the NBTR and the MRC Sudden Death Brain and
Tissue Bank, Edinburgh (Table S1). There are no statisti-
cally significant differences in age (Mann–Whitney U test,
P value = 0.3390) and post-mortem interval (PMI; Mann-
Whitney U test, P value = 0.6209) in patients and con-
trols selected. Patient details are summarized in Table 1
[9,21–23]. Newcastle and North Tyneside Local Research
Ethics Committee (LREC2002/205) approved this study,
and full consent for brain tissue retention and research
was obtained.
The patients with mitochondrial disease were clinically
assessed using the validated Newcastle Mitochondrial
Disease Adult Scale (NMDAS) [24] (Table 1) within 1 year
of death. NMDAS scores for cerebellar ataxia confirmed
cerebellar ataxia in all patients included in the study.
Scaling varies from 0 to 5 where 0 is unaffected and 5 is
wheelchair dependent.
Two-dimensional neuron counting and neuronal
density calculation
Neuron densities for Purkinje cells and dentate nucleus
neurons have been documented using a two-dimensional
counting protocol previously described [9]. In this study,
quantification of Purkinje cell and dentate nucleus
neuronal density was performed for Patients 3, 8 and 10
(Table 1) as they were not included in the previous study.
Immunofluorescence to detect mitochondria and
complex I in Purkinje cells and their synapses
Immunofluorescence was performed on 5 μm-thick FFPE
sections of cerebellar tissue mounted on SuperFrost
slides (ThermoScientific, UK). Immunofluorescence
was performed on positive controls (all antibodies),
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no-primary-antibody and no-secondary-antibody (NSA)
controls for each of the four fluorophores to allow for back-
ground correction and cross-reactivity checks respectively
(Figure S1). Sections were deparaffinized and rehydrated
by placing in a 60°C oven for 20 min, followed by immer-
sion in Histoclear (National Diagnostics, Charlotte, NC,
USA) and graded ethanol series (100% to 70%) to water.
Antigen retrieval was performed using the 2100 retriever
unit (Electron Microscopy Sciences©, Hatfield, PA, USA)
which involved immersionof sections in1 mmolEDTA(pH
8) and pressure cooking for 40 min. Sections were blocked
in 1% normal goat serum (NGS) for 1 h at room tempera-
ture (RT) and incubated in primary antibodies at the
optimal dilution overnight at 4°C. Mouse monoclonal
primary antibodies used were directed against nDNA-
encoded respiratory chain complex subunits, NADH
dehydrogenase [ubiquinone] 1 alpha subcomplex subunit
13 (anti-NDUFA13; Abcam, UK, ab110240) and
cytochrome c oxidase subunit 4 (anti-COX4 (+4L2);
Abcam, UK, ab110261), and a presynaptic protein
synaptophysin (anti-SY-38; DAKO, UK, M0776). A rabbit
polyclonal antibody was directed against Glutamic acid
decarboxylase (anti-GAD-65/67; Sigma-Aldrich, UK,
G5163) (Table S2). Following incubationwith theprimary
antibodies, sections were washed with 10 mM phosphate-
buffered saline (3 × 5 min) and subjected to a biotinylated
secondary antibody incubation (Biotin-XX goat anti-
mouse IgG1; LifeTechnologies, UK,A10519) for 30 minat
RT. Quadruple immunofluorescent labelling involved sec-
ondary anti-mouse antibodies conjugated with Alexa
Fluor 488 and 546, anti-rabbit conjugated with Alexa
Fluor 405 antibody and streptavidin-conjugated
Alexa Fluor 647 antibody (Life Technologies, UK)
(Table S2). The signal-to-noise ratio was increased by
quenching thebackground signalwith3%SudanBlack for
10 min. Sections were then washed in distilled water and
mounted in Prolong Gold (Life Technologies, UK).
Confocal microscopy
Purkinje cells and synapses were imaged on x, y and z
planes using an inverted point scanning confocal micro-
scope (Nikon A1R, UK). Areas of interest (either dentate
nucleus neurons or Purkinje cell bodies) were detected
using an immersion oil ×60 objective with numerical
aperture of 1.4. Twenty Purkinje cells and dentate
nucleus neurons were randomly sampled per case using
an electronic zoom of ×3 (× 180 magnification).
Z-stacking was performed according to the recommended
microscope settings (pixel size: 0.14 μm; z-step size:
0.17 μm; optical resolution: 0.13 μm and optical sec-
tioning: 0.54 μm). Four lasers were employed (405 nm,
488 nm, 561 nm and 647 nm), each detecting the
signal from a different fluorophore. Microscope and laser
settings were maintained throughout image capture.
Laser stability and point spread function (PSF)measure-
ments were achieved using FocalCheck™ Fluorescence
Microscope Test slides (Molecular Probes™, Invitrogen,
UK) andTetraSpeck™ Fluorescent Microsphere Standards
(Invitrogen, UK) respectively.
Image processing and three-dimensional
reconstruction of synapses
To investigate complex I (NDUFA13) and complex IV
(COX4) protein expression in either Purkinje cell
bodies or GABAergic synapses, three-dimensional images
were analysed using Volocity® 3D image analysis and
deconvolution software (v.6.1.1, PerkinElmer, UK). Ini-
tially, all the images were cropped to single neurons;
these were then deconvolved in three dimensions using
measured PSFs.
Purkinje cells are the sole output of the cerebellar
cortex and the only neurons to project inhibitory
(GABAergic) synapses to deep cerebellar nuclei, such as
the dentate nucleus [25]. Purkinje cells project their
GABAergic axonal terminals onto dentate nucleus
neurons, forming axosomatic inhibitory synapses. Differ-
ent analysis protocols were developed depending on the
cerebellar neuron (Purkinje cells vs. dentate nucleus
neurons) and subneuronal compartment (cell bodies vs.
GABAergic presynaptic terminals) of interest.
Glutamic acid decarboxylase 65/67 (GAD-65/67) is
uniformly and highly expressed in GABAergic neuronal
cell bodies (GAD67) and inhibitory presynaptic terminals
(GAD65) [26]. Synaptophysin is a component of
presynaptic terminals and demonstrates variably strong
puncta surrounding neuronal cell bodies. COX4 protein
expression was strong, and the pattern of staining was
uniform and punctate in both patients and controls in
agreement with previous studies that rarely report its
loss from the cerebellum [9] and therefore justifying its
use as a mitochondrial mass marker. Complex I subunit
NDUFA13 was selected as a marker for complex I defi-
ciency as decreased NDUFA13 protein expression was
previously detected in our patients [9], and because this
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antibody has a different isotype to the remaining three
antibodies used, therefore avoiding antibody cross-
reactivity. Therefore, by using NDUFA13 in combination
with COX4, we can determine the relative loss of this
complex I subunit.
For synaptic sampling, GAD-65/67 and SY-38 positive
puncta on the periphery of dentate nucleus neurons
were originally detected as separate objects using the
‘automatic threshold’ function of the software. Areas of
colocalization between these two populations were then
defined as GABAergic synapses using the ‘exclusively
combine’ command, creating a third population.
Mitochondrial ‘objects’ were identified separately using
the COX4 channel as a reference, while the synaptic
mitochondrial population deviated after ‘compartmental-
izing’ mitochondrial objects between GABAergic syn-
apses. For Purkinje cell sampling, regions of interest
(ROIs) were manually drawn and included the neuronal
cell bodies. Mitochondrial ‘objects’ were recognized
within each ROI, and protein intensity measures were
taken from these. Detailed information on the develop-
ment of each protocol is summarized in Figures 1 and 2.
As image capture was performed on all x-, y- and
z-planes, 3D reconstruction of synapses was possible,
and this allowed synaptic numbers and size (volume) to
be determined.
Figure 1. Detecting and quantifying mitochondrial protein expression in Purkinje cells. Quadruple immunofluorescence of cerebellar
Purkinje cells against Glutamic acid decarboxylase (GAD-65/67), synaptophysin (SY-38), complex IV subunit 4 (COX4) and complex 1
alpha subcomplex subunit 13 (NDUFA13). GAD-65/67 is used to detect GABAergic cell bodies and inhibitory synapses. Combined with SY-
38 indicates the convergence of inhibitory presynaptic terminals. COX4 is a mitochondrial mass marker, and NDUFA13 protein is used to
detect complex I deficiency. Control Purkinje cells demonstrate co-localization of COX4 and NDUFA13 protein, indicating intact complex I
expression, while NDUFA13 protein is significantly reduced in patient Purkinje cells (complex I-deficient). Purkinje cells in the three
examples shown above (Patients 1, 8 and 11) exhibit variably decreased NDUFA13 protein relative to the amount of COX4 present. Scale
bar: 7 μm.
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Statistical analysis
For each area of interest (Purkinje cell body or GABAergic
presynaptic terminal), the mean optical density (OD) of
NDUFA13 and COX4 immunofluorescence was measured
(Volocity®, UK, PerkinElmer, UK) and background cor-
rected. The background-corrected OD values were log
transformed to normalize the data (yielding COX4T and
NDUFA13T). Themean and standard error for distribution
of COX4T were estimated, as well as the regression param-
eters and the standard error of the estimate for the regres-
sion of NDUFA13T against COX4T. For each area of
interest, the z score for the COX4 level was calculated, and
the z score for NDUFA13 (NDUFA13Z) was calculated
using the linear regression based on the level of COX4.
Finally, Purkinje cells and/or GABAergic presynaptic ter-
minals were classified based on standard deviation limits
(for NDUFA13: normal if −2 < z < 2SD, low if z <−2SD,
deficient if z <−3SD and very deficient if z <−4SD).
Once the z scores were derived, two-sample t (for
parametric data) and Mann–Whitney U tests (for
nonparametric data)were performed to examine the differ-
ences in NDUFA13 and COX4 protein expression between
different neuronal sub-compartments or patients with dif-
Figure 2. Detecting synaptic mitochondria and reconstructing GABAergic synapses. Development of the protocol for detecting and
reconstructing GABAergic presynaptic terminals onto dentate nucleus neurons. Top panel: Confocal images of immunofluorescently stained
control dentate nucleus neurons were used to identify inhibitory synapses. Scale bar: 7 μm. Magnified view: Areas around the periphery of
neurons where GAD-65/67 (blue) and synaptophysin (purple) puncta coexist are denotative for the presence of inhibitory synapses.
COX4-positive staining (red) indicates mitochondrial mass, and NDUFA13 presence (green) is used to detect respiratory chain protein
deficiency. Scale bar: 1.5 μm. Object detection: Actual staining substituted by objects that represent each of the four markers used.
Mitochondrial objects can then be compartmentalized and filtered so that only the ones that are within synapses are studied (far right).
Bottom panel: Three-dimensional reconstruction of inhibitory synapses on the same control neuron, and identification of synaptic
mitochondria. Scale: 1 unit = 1.56 μm. Protocol development is achieved using the Volocity® software (v.6.3.1, PerkinElmer).
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ferent genetic defects. For testing paired nonparametric
data, the Wilcoxon signed-rank test was employed. Age,
fixation time and PMI differences between patients and
controls were tested using nonparametric Mann–Whitney
U test. Spearman’s correlation coefficient was used to test
associations between continuous variables.
Statistical analyseswere carried out using sas9.3 (Cary,
NC, USA) and Minitab® (16.1.0, UK).
We have not used Bonferroni or other adjustments for
multiple testing in our analyses; where we are testing a
priori hypotheses, this is appropriate [27]. However, the
potential for more frequent type I statistical errors must be
considered in interpretation of the P values resulting from
these analyses.
Laser microdissection, DNA extraction and
pyrosequencing for mtDNA heteroplasmy in
Purkinje cells and synapses
Sections of 15 μm-thick frozen cerebellum mounted onto
SuperFrost slides were subjected to double immunofluo-
rescence for laser microdissection. The sections were typi-
cally left to air dry for 1.5 h and were fixed with 4%
paraformaldehyde for 10 min at RT. Following this, sec-
tions were washed with Tris-buffered saline (TBS) (two
times × 2 min and one time × 10 min), blocked with 10%
NGS for 30 min at RT and incubated in primary antibody
solution overnight at 4oC. Primary antibodies included
anti-SY-38 and anti-GAD-65/67 (Table S2). Sectionswere
then washed with 10 mM TBS (three times × 5 min) and
subjected to a biotinylated secondary antibody incubation
(Biotin-XX goat anti-mouse IgG1) (A10519, Life Tech-
nologies, UK) for 30 min at RT. A secondary anti-goat
antibody conjugated with Alexa Fluor 488 (Life Technolo-
gies, UK) and a streptavidin-conjugated Rhodamine Red-X
antibody (Jackson ImmunoResearch laboratories West
Grove, PA, USA) were applied for 2 h at 4oC enabling
double immunofluorescent labelling. Tissue auto-
fluorescence was blocked by incubating with 3% Sudan
Black for 3 min.
Purkinje cells were identified using the 488 nm channel
(fluorophore coupled to anti-GAD-65/67 antibody) and
isolated at × 40 magnification using the ‘close-cut and
AutoLPC’ function on a PALM MicroBeam Laser
microdissection microscope (Zeiss microscopy, UK).
Inhibitory synapses to the dentate nucleus were recog-
nized under the × 63magnification as regions where both
GAD-65/67 and synaptophysin were localized and iso-
lated using the ‘centre RoboLPC’ function. Laser dissected
tissue was then subjected to overnight lysis using 10 μl of
a DNA lysis buffer prior to PCR [28].
Extracted DNA was subjected to two rounds of PCR
amplification using a biotinylated forward and reverse
primer (Integrated DNA Technologies, Glasgow, UK)
that would span the site of mutation (Table S3).
Pyrosequencingwas performed according to themanufac-
turer’s instructions using a Pyromark Q24 platform
(Qiagen, UK) and a mutation-specific sequencing primer.
The Pyromark Q24 software was employed to define
mtDNA heteroplasmic levels by comparing the peak
heights of mutant, wild-type and known-heteroplasmy
mtDNA at the site of interest [29].
Results
Measuring respiratory chain protein expression
using quadruple immunofluorescence
A subset of patients have been investigated previously
using COX/SDH immunohistochemistry and other con-
ventional immunohistochemical methods which relied
upon the visualization of proteins using chromogens [9].
In this study, we have used a quantitative quadruple
immunofluorescence technique in order to measure res-
piratory chain protein expression both in cell bodies and
synaptic terminals. A similar approach to determine
mitochondrial respiratory chain protein expression
has recently been described in substantia nigra neurons
and confirms the accuracy and reproducibility of the
assay [30]. The current assay uses antibodies which are
fluorescently labelled to allow visualization and quantifi-
cation of COX4, NDUFA13, SY-38 and GAD-65/67
protein expression to look at mitochondrial
mass, complex I, synaptophysin, and GABAergic cell
bodies (Figure 1) and nerve terminals (Figure 2)
simultaneously.
Complex I deficiency detected in Purkinje cells
Purkinje cell bodies were identified by diffuse staining of
GAD-65/67 throughout the cell body (Figure 1). In
control neurons, mitochondria (as judged by COX4
expression) were abundant and showed co-localization
with complex I subunit (NDUFA13). There was no differ-
ence in COX4 protein expression between patient and
control Purkinje cells (two-sample t test, P = 0.323) in
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agreement with previous studies that rarely report defi-
ciency of this protein [9]. However, in some Purkinje cells
from patients, there was loss of NDUFA13, indicating
complex I deficiency (Figure 1), while in Basket cells,
NDUFA13 appeared intact. Quantification of protein
expression confirmed complex I deficiency and enabled
comparison between patient and control neurons in order
to explore the severity of the defect. Complex I deficiency
(z <−3SDs) was observed in patients carrying the
m.3243A > Gmutation (Patients 1, 3 and 5) and a patient
carrying autosomal recessive POLG mutations (Patient
11), while decreased complex I levels (z <−2SDs) were
observed in patients with m.3243A > G (Patient 4 and 6)
and m.8344A > G (Patient 7) point mutations (Figure 3).
Our data showed Purkinje cell deficiency is more severe in
patients with the m.3243A > G point mutation compared
with the level of deficiency in the other patients when
genetic defects were grouped (m.8344A > G,
m.14709T > G and POLG) (Mann–Whitney U test,
P = 0.0306). There was considerable variation in the
extent of deficiency between patients with the same
genetic defect as has previously been reported [9]. Spear-
man’s rank correlation analysis showed that PMI (Spear-
man’s rank rho = −0.242, P = 0.449) and fixation time
(rho = −0.035, P = 0.913) did not affect the derived z
score values for complex I deficiency in Purkinje cells.
Complex I deficiency in GABAergic
presynaptic terminals
Evaluation of Purkinje cell synapses on dentate nucleus
neurons revealed matched expression of NDUFA13 and
Figure 3. NDUFA13 protein expression in Purkinje cells and their inhibitory synapses on the dentate nucleus. Complex I deficiency in
patient cerebellar Purkinje cells and inhibitory synapses is expressed as z score values. Coloured box plots represent Purkinje cell z values,
and clear boxplots reflect inhibitory synapse z values. In Purkinje cells, the most severe deficiency is generally observed in patients with the
m.3243A > G point mutation (Patients 1–6), with Patient 5 (m.3243A > G) showing the most dramatic loss of NDUFA13 protein expression
(Median z score = −12). Two individuals with recessive POLG mutations (Patient 9 and 10) demonstrate relatively high NDUFA13 protein
expression. Patients with the same genetic defect show variability in their complex I expression (Patient 2 vs. Patients 1 and 3 for
m.3243A > G; Patient 7 vs. Patient 8 for m.8344A > G). In inhibitory synapses, the majority of patients revealed variably decreased complex
I expression, with Patients 5 (m.3243A > G) and 11 (POLG) possessing the most deficient synaptic terminals, while Patients 2
(m.3243A > G) and 10 (POLG) are not different from controls.
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COX4 in control tissue. In patient tissue, it was clear
that some synapses had low expression of NDUFA13
(Figure 4). Protein intensity quantification confirmed no
difference in COX4 expression in control and patient syn-
apses (two-sample t test, P = 0.620); however, NDUFA13
relative to COX4 intensity levels confirmed decreased
expression and low z scores compatible with complex I
deficiency (z <−3SDs) (Figure 3; Table 2). This respiratory
chain deficiency is variable, with patient synapses demon-
strating either a minor (Patient 1; m.3243A > G muta-
tion) or a severe (Patient 11, recessive POLG mutations)
decrease in NDUFA13 expression despite maintained
COX4 expression (Figure 4). Similar to Purkinje cells, syn-
aptic NDUFA13 deficiency was seen in patients with differ-
ent genetic defects, but there was considerable variability
in the extent of deficiency even in patients with the same
genetic defect. Complex I deficiency in inhibitory
presynaptic terminals was not affected by either PMI
(rho = −0.126, P = 0.696) or fixation time (rho = −0.007,
P = 0.983) (Spearman’s rank correlation).
Analysis of NMDAS scores and NDUFA13 expression in
synapses reveals a statistically significant relationship
between higher NMDAS scores, indicating a more severe
ataxia, and lower z scores, indicating more complex I defi-
ciency (Spearman’s rho = −0.60, P value = 0.0493)
(Figure 5).
Comparison of complex I deficiency in Purkinje
cells and in GABAergic presynaptic terminals
For both Purkinje cells and their synapses, there is consid-
erable variation between patients in the degree of defi-
ciency observed. While patients harbouring the
m.3243A > G showed significantly more complex I defi-
ciency in Purkinje cells than the other patients when these
were grouped, this was not true for the level of deficiency
in synapses, which was comparable in all patients
(Figure 3). Interestingly, while all patients with the
m.3243A > G mutation showed more deficiency (lower
median z scores) in Purkinje cell bodies than synapses, all
patients in the group of other mutations (m.8344A > G,
m.14709T > C and POLG mutations) showed the reverse
trend. The difference between these two groups was statis-
tically significant (Mann–Whitney U test, P = 0.0051),
though this was not an a priori hypothesis and the P value
needs to be interpretedwith caution.There is no difference
in complex I expression levels between Purkinje cell bodies
and GABAergic synapses in the group of patients as a
whole (Wilcoxon signed-rank test of differences between z
scores in Purkinje cells and synapses, P = 0.666).
GABAergic synaptic loss and remodelling
The majority of patients (Patients 1, 2, 4, 5, 7, 9–11)
revealed a decrease in the number of GABAergic
presynaptic terminals on dentate nucleus neurons relative
to controls (Figure 6) though this decrease lies within the
±2 SDs limits. This suggests synaptic loss in conjunction
with Purkinje cell loss (Table 1), and indeed, there is a
correlation between Purkinje cell loss and the loss
of inhibitory synapses on dentate nucleus neurons
(Spearman’s rank correlation coefficient = −0.74; P
value = 0.02). Patients 3, 8 and 12 do not demonstrate
synaptic loss, which can be explained by preservation of
Purkinje cells (Table 1). Interestingly, there is also a corre-
lation between the number and the size (volume) of
GABAergic synapses in patients with an increase in
volume of residual inhibitory synapses when there
is synaptic loss (Spearman’s rank correlation coeffi-
cient = −0.615; P value = 0.037). Synaptic numbers and
volume were not affected by PMI (rho = 0.143, P = 0.736
for synaptic numbers and rho = 0.595, P = 0.120 for syn-
aptic volume) or by fixation length (rho = 0.011,
P = 0.980 for synaptic numbers and rho = −0.688,
P = 0.059 for synaptic volume) (Spearman’s rank
correlation).
MtDNA heteroplasmy in Purkinje cell bodies vs.
inhibitory presynaptic terminals
Assessment of mutated mtDNA heteroplasmy for
m.3243A > G and m.8344A > G in both Purkinje cells
and inhibitory synapses did not show any significant dif-
ference in the levels of mutated mtDNA between the two
neuronal sub-compartments (Wilcoxon signed-rank test
of differences between mutation load percentage in
Purkinje cells and synapses, P = 1) (Figure 7).
Discussion
Cerebellar dysfunction due to mitochondrial impairments
is increasingly recognized as an important cause of ataxia.
Ataxia is common and an important cause of disability
in patients with mitochondrial disease [8,31,32].
Neuropathological studies provide important clues into
disease mechanisms and reveal that Purkinje cells are
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Figure 4. Complex I deficiency in inhibitory synapses on dentate nucleus neurons. Quantification of NDUFA13 protein expression in
GABAergic synapses around dentate nucleus neurons (top panel; scale bar: 7 μm). Control inhibitory synapses have equal expression of
COX4 (mitochondrial mass) and NDUFA13 (white arrows – left panel), indicating intact complex I expression. In contrast, mitochondria in
patient inhibitory presynaptic terminals have decreased complex I expression (white arrows), indicating mitochondrial dysfunction in these
synapses. There is a severe reduction in complex I expression relative to mitochondria (Patient 5; m.3243A > G), while in other patients,
there is only a small difference in complex I to COX4 expression (Patient 11; POLG). Scale bar: 1.5 μm.
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particularly vulnerable to degeneration and cell death. In
this study, we aimed to clarify the impact of mitochondrial
defects on the microcircuitry of the cerebellum by
focussing on the GABAergic Purkinje cells and their
synapses. To achieve this, we have used a quadruple
immunofluorescent technique to detect complex I within
mitochondria in GABAergic synapses from 12 patients.
We show that complex I deficiency is present in both
Purkinje cell bodies and their inhibitory synapses, with no
overall difference in NDUFA13 expression between the two
regions. There was loss of synapses in some patients, and
this was associated with enlarged remaining presynaptic
terminals. Finally, in those patients with heteroplasmic
mtDNA point mutations, we observed no difference in
mtDNA mutation level between Purkinje cell bodies and
their synapses.
Previous neuropathological studies of patients with
mitochondrial disease have shown a positive relationship
between neuronal cell loss and high respiratory chain defi-
ciency in remaining cells [9]. In the majority of previous
studies, mitochondrial protein changes are assessed using
conventional histochemical (sequential COX/SDH reac-
tion) and immunohistochemical methods. These are
limited because they are subjective and only enable the
reliable detection of cells with either complete loss of
enzyme/protein expression or high enzyme/protein levels
without correcting for mitochondrial mass. Hence, any
mild or intermediate changes in respiratory chain protein
expression may be overlooked. We recognized the need to
use an accurate and reliable method to document respira-
tory chain deficiency and therefore employed quadruple
immunofluorescence in order to precisely and reliablyTa
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Figure 5. Correlation between NMDAS score for cerebellar ataxia
and NDUFA13 protein expression in inhibitory presynaptic
terminals. More severe ataxia scores are related to lower z scores for
NDUFA13 expression (Spearman’s rho = −0.60, P value = 0.0493).
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quantify respiratory chain protein expression within spe-
cific cell types and their sub-cellular domains. We quanti-
fied complex I deficiencies in Purkinje cells and their
GABAergic presynaptic terminals through the use of four
fluorescently labelled protein markers, labelling mito-
chondria, complex I, GABA-expressing neurons and syn-
apses. Previous studies have shown that the NDUFA13
subunit plays an essential role in the assembly and activity
of complex I, and indeed a recent study reports NDUFA13
mutations which lead to complex I instability [33]. Due to
a lack of available histochemical assays to measure
complex I activity at the single cell level in tissues,
however, we cannot measure complex I activity biochemi-
cally. We infer that NDUFA13 expression with a z score of
−3 or less suggests complex I deficiency which is likely to
correlate with loss of complex I activity.
We show that Purkinje cell bodies and their synaptic
terminals have decreased protein expression in patients
relative to controls. This is a significant observation for
Purkinje cells from patients with the m.3243A > G muta-
tion where prominent complex I deficiency was observed.
This is consistent with previous studies in skeletal muscle
from patients with m.3243A > G and m.8344A > G
mutations where low complex I activity and low expres-
sion of complex I subunits are a common finding [34–36].
NDUFA13 protein expression is decreased in patients with
different genetic defects, and protein deficiency is seen in
both Purkinje cell bodies and inhibitory presynaptic ter-
minals. Overall, the degree of complex I expression is
similar between the two neuronal domains. It is interest-
ing that NDUFA13 deficiency in synapses correlates well
with ataxia which suggests that synaptic pathology could
contribute to mitochondrial disease pathogenesis in these
patients.
In addition, for those patients with heteroplasmic
mtDNAmutations, molecular genetic investigation shows
that the levels of mutated compared with wild-type
mtDNA are similar between Purkinje cell bodies and their
Figure 6. Changes in the number of inhibitory presynaptic terminals. The number of GABAergic synapses counted on each dentate
nucleus neuron (n = 20) expressed as z score values. Decreased numbers of inhibitory presynaptic terminals is detected in eight out of 12
patients. All patients with recessive POLG mutations exhibit synapse loss, in addition to the majority of patients harbouring the
m.3243A > G point mutation. Intriguingly, Patients 3 (m.3243A > G), 8 (m.8344A > G) and 12 (m.14709T > C) have increased numbers
per cell compared with controls.
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inhibitory synapses which are consistent with the equiva-
lent level of NDUFA13 deficiency in both compartments.
Damaged mitochondria are recycled via a process
known as mitophagy that takes place in the neuronal cell
body [37]. Under normal conditions, dysfunctional synap-
tic mitochondria are retrogradely transported back to the
cell body to undergo recycling, leaving the synapse with
healthy organelles that would be able to provide the region
with energy [38]. Comparable levels of NDUFA13 expres-
sion and heteroplasmic mtDNA between Purkinje cell
bodies and GABAergic synapses in patients were observed,
andwe are uncertainwhy the deficientmitochondriawere
not retrogradely transported for degradation.
Mitochondrial function is important for sustaining
activity-dependent energy requirements in the
presynaptic terminal [39]. Mitochondrial-generated ATP
is required for efficient neurotransmission by fuelling syn-
aptic vesicle docking to the presynaptic membrane and
neurotransmitter release and uptake to/from the synaptic
cleft [40,41]. Moreover, complex I activity has been dem-
onstrated to be a critical factor for synaptic oxygen con-
sumption [17,18], while regulation of the mitochondrial
calcium buffering capacity is important for recovery fol-
lowing repetitive depolarization [7]. It is therefore likely
that presynaptic complex I deficiency would be detrimen-
tal for normal synaptic activity.
Reconstruction of GABAergic presynaptic terminals
allowed us to evaluate synaptic numbers and size. The
number of inhibitory contacts detected on dentate
nucleus neurons is decreased in the majority of patients,
while synaptic volume is increased. We speculate that this
could be a compensatory mechanism in an attempt to
maintain contact area by adjusting synaptic volume in
case of contact loss. This would be in agreement with
previous ultrastructural studies in the frontal cortex of
patients with Alzheimer’s disease where a strong negative
correlation was found between synaptic contact size and
density [42].
Post-mortem studies in common neurodegenerative
diseases including Alzheimer’s, Huntington’s and Parkin-
son’s have suggested that loss of synapses occurs as an
early event, prior to loss of the neuronal cell body, a
Figure 7. MtDNA mutation load in isolated Purkinje cells and inhibitory presynaptic terminals. Heteroplasmy levels for individually isolated
Purkinje cell bodies and inhibitory presynaptic terminals from five patients harbouring mtDNA point mutations (m.3243A > G and
m.8344A > G). Individual symbols represent independent read-outs, and bars represent medians (n = 15 for both populations).
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process known as ‘dying-back’ [43,44]. Investigating
whether this is also applicable in the case of mitochondrial
disease is interesting but also challenging as our study is
performed on post-mortem human brains and represents
end-stage disease. The correlation between synaptic
contact numbers and the percentage of Purkinje cell loss
suggests that the documented changes on synapse
numbers might simply be a reflection of Purkinje cell
loss. Further studies using an animal model would
provide greater insights into temporal evolution of
neurodegeneration and would be a useful approach to
understand whether synaptic abnormalities precede
neuronal cell loss.
Conclusion
In this study, we have quantified mitochondrial respira-
tory chain complex I expression in Purkinje cells and their
inhibitory projections and provided quantitative evidence
of morphological abnormalities in synapses in patients
with mitochondrial disease and ataxia. Our data suggest
that patients harbouring the m.3243A > G mutation
show the highest levels of complex I deficiency in Purkinje
cells. However, in general, there is no difference in the
level of deficiency between the two neuronal sub-
compartments, and in those patients with heteroplasmic
mtDNA mutations, there are similar levels of mutated
mtDNA. We report fewer GABAergic synapses and
enlarged residual synapses contacting the dentate
nucleus, which could suggest altered cerebellar circuitry
that might contribute to ataxia seen in these patients.
Further work is crucial to dissect out the impact of
complex I deficiency on neurons and their synapses in a
functional system to understand the mechanisms of
degeneration in mitochondrial disease.
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